A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer (BEVAMAINT)

• ClinicalTrials.gov Identifier: NCT04188145
• Recruitment Status: Recruiting
• First Posted: December 5, 2019
• Last Update Posted: October 28, 2021
• Sponsor: Centre Hospitalier Universitaire Dijon
• Information provided by (Responsible Party): Centre Hospitalier Universitaire Dijon

Tracking Information

• First Submitted Date: December 3, 2019
• First Posted Date: December 5, 2019
• Last Update Posted Date: October 28, 2021
• Actual Study Start Date: January 27, 2020
• Estimated Primary Completion Date: September 2023 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: December 3, 2019)

The Time-to-Treatment Failure (TTF) [ Time Frame: 8 months ]

Will be calculated from date of randomization (after the end of induction chemotherapy) to first radiological progression (according to RECIST 1.1) or death or start of a new chemotherapy (induction regimen or second line) or end of maintenance treatment without further chemotherapy, even if there is no radiological progression. Patients alive with no radiological progression and under maintenance treatment will be censored at the date of last news.

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: December 3, 2019)

• Progression-free survival (PFS1) [ Time Frame: 16 months ]
  Defined as the time between randomization and the first radiological progression (according to RECIST 1.1) or death (whatever occurs first). Patients alive and without progression will be censored at the date of last news.
• Progression-free survival (PFS2) [ Time Frame: 16 months ]
  Defined as the time between the end of maintenance treatment (whatever the reason is) and the radiological progression after this end of maintenance treatment or death whatever the cause. Patients alive and without progression will be censored at the date of last news.
• Overall Survival (OS) [ Time Frame: 3 years ]
  Defined as the time between randomization and death (any cause). Patients alive will be censored at the date of last news.
• Safety [ Time Frame: 3 years ]
  Toxicities will be graded according to the NCI-CTC v 4.0 criteria before each cycle.
• Quality of Life (QoL) [ Time Frame: 3 years ]
  Assessed at each evaluation with a questionnaire

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer
• Official Title: A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer
• Brief Summary: The aim of BEVAMAINT is to improve benefic effect of maintenance therapy after a first line of induction chemotherapy for patients with colorectal cancer
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Metastatic Colorectal Cancer

Intervention

• Drug: Fluoropyrimidine

  Option 1: Capecitabine 1250 mg/m2 twice daily (i.e. 2500 mg/m²/d) (D1 to D14, D1 = D22) For frail patients according to investigator evaluation capecitabine dose may be reduced to 1000 mg/m2 twice daily (2000 mg/m²/d).

  Or Option 2: Capecitabine 625 mg/m2 twice daily (i.e. 1250 mg/m²/d) (D1 to D21, D1 = D22) Or Option 3: LV5FU2 simplified (folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h followed by 5-FU bolus IV of 400 mg/m² during 10 min and IV continuous 5-FU at 2400 mg/m² during 46h). (D1=D15).

• Drug: Bevacizumab

  Option 1 and Option 2 : D1 bevacizumab 7.5 mg/kg IV (D1=D21). See smPCs for infusion time of bevacizumab.

  Or Option 3: D1 bevacizumab 5 mg/kg IV (D1=D15). See smPCs for infusion time of bevacizumab

Study Arms

• Active Comparator: Fluoropyrimidine
  Intervention: Drug: Fluoropyrimidine
• Active Comparator: Fluoropyrimidine + Bevacizumab
  Interventions:

  • Drug: Fluoropyrimidine
  • Drug: Bevacizumab

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: December 3, 2019): 400
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: December 2025
• Estimated Primary Completion Date: September 2023 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Histologically confirmed metastatic colorectal adenocarcinoma before induction treatment
• Measurable or non-measurable lesion before the induction treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
• Metastatic, unresectable disease according local practice after induction treatment
• ECOG performance status ≤ 2
• Disease control (complete response, partial response or stable disease) after 4-6 months of frontline induction chemotherapy with doublet (fluoropyrimidine + irinotecan or oxaliplatin) or triplet (fluoropyrimidine + irinotecan + oxaliplatin) +/- (cetuximab, panitumumab, bevacizumab) or IAH chemotherapy
• Life expectancy > 3 months
• Age ≥ 18 years
• Patient is at least 4 weeks from any major surgery
• Total bilirubin < 25 µmol/L, ASAT < 3 x ULN, ALAT < 3 x ULN (ASAT , ALAT < 5 x ULN in case of hepatic metastasis) , PT >60% , PAL<2.5 x ULN ( < 5 x ULN in case of hepatic metastasis) - Neutrophils > 1500/mm3, platelets > 100 000/mm3, haemoglobin ≥ 9 g/dL
• Creatinin clearance > 30 ml/min (MDRD) - if creatinin clearance comprised between 30 and 50 ml/min, see smPCs for dose adjustments
• Proteinuria ≤ 2+ (dipstick urinalysis) (if more than 2+, so proteinuria at or ≤1g/24hour must be ≤1g)
• Patient is able to understand, sign, and date the written informed consent
• Evidence of post-menopausal status or negative urinary or serum pregnancy test for premenopausal female patients
• Male and female patients of childbearing potential agree to use a highly effective contraceptive measure
• Patient affiliated to a social security system

Exclusion Criteria:

• Myocardial infarction, severe coronaropathy or severe cardiac dysfunction less than 6 months prior randomization
• Follow-up impossible
• Patients with all metastases resected (R0/R1) after induction chemotherapy
• Patient with a hand-foot syndrome > 1 before maintenance treatment
• Known brain or leptomeningeal metastases
• Other concomitant or previous malignancy, except: adequately treated in situ carcinoma in complete remission for > 5 years
• Uncontrolled hypertension (defined as systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy
• Pregnancy or breast feeding
• Treatment with sorivudine or analogs (brivudine)
• Treatment with phenytoin or analogs
• Partial or complete DPD deficiency (Uracilemia ≥ 16 ng/ml)
• Peptic ulcer not healed after treatment
• Any contraindication to bevacizumab or fluoropyrimidine treatments according to the updated SmPC
• Intestinal perforation or intestinal fistula
• Previous or active gastrointestinal bleeding
• Thromboembolic event and/or history of thromboembolic event
• Severe hepatic insufficiency

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Thomas Aparicio; (0)1 42 49 95 97 ext +33; thomas.aparicio@aphp.fr

• Listed Location Countries: France

Administrative Information

• NCT Number: NCT04188145
• Other Study ID Numbers: PRODIGE 71
• Has Data Monitoring Committee: Not Provided

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Centre Hospitalier Universitaire Dijon
• Original Responsible Party: Same as current
• Current Study Sponsor: Centre Hospitalier Universitaire Dijon
• Original Study Sponsor: Same as current
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: Centre Hospitalier Universitaire Dijon
• Verification Date: October 2021